A Case Report of a Pregnant Woman with Chronic Hepatit B: Use of Tenofovir in Pregnancy

Year 2020, , 82 - 84, 01.03.2020

Hülya Güven M. Aylin Arıcı Gözde Aktürk Özge Güner

https://doi.org/10.30621/jbachs.2020.807

Abstract

Objective: To overview the effects of tenofovir use in chronic Hepatit B in pregnancy and asses the effects on the vertical transmission of HBV from mother to baby. Case Report: We presented a pregnant woman who has Chronic Hepatit B with high viral load in the 26th week of her pregnancy. She took tenofovir in the 37th week of her pregnancy once a day along six days. Then she gave birth to a healthy baby at the 37th week of the pregnancy. Hepatit B Immunoglobulin HBIG and Hepatit B vaccine had applied to the baby. In the follow-up, the mother’s viral load was decreased. HBV DNA was not detected in the baby. Conclusion: Only six-day tenofovir use in this pregnant woman with chronic Hepatit B may contribute to preventing vertical transmission of HBV from mother to baby. However, the importance of HBIG and vaccination should not be forgotten

Keywords

Tenofovir, chronic Hepatit B, pregnancy, vertical transmission

References

• Ehrhardt S, Xie C, Guo N, Nelson K, Thio CL. Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence. Clin Infect Dis 2015;60:275–278. [CrossRef]
• Gentile I, Borgia G. Vertical transmission of hepatitis B virus: challenges and solutions. Int J Womens Health 2014;6:605. [CrossRef]
• Celen MK, Mert D, Ay M, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol 2013;19:9377– 9382. [CrossRef]
• Wakano Y, Sugiura T, Endo T, et al. Antiviral therapy for hepatitis B virus during second pregnancies. J Obstet Gynaecol Res 2018;44:566– 569. [CrossRef]
• Kwon H, Lok AS. Viral hepatitis and pregnancy. Clin Liver Dis 2014;4:55–57. [CrossRef]
• Pan CQ, Mi L, Bunchorntavakul C, et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci 2012;57:2423–2429. [CrossRef]
• Ayoub WS, Cohen E. Hepatitis B management in the pregnant patient: An update. J Clin Transl Hepatol 2016;4:241–247. [CrossRef]
• Jaffe A, Brown RS. A review of antiviral use for the treatment of chronic hepatitis B virus infection in pregnant women. Gastroenterol Hepatol (N Y) 2017;13:154–163. https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC5439134/pdf/GH_13_154.pdf
• Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry Interim Report for 1 January 1989 through 31 January 2018. Wilmington, NC. Registry Coordinating Center; 2017. Available from: http://www.apregistry.com/
• Zeng J, Zheng C, Li H. Effectiveness of tenofovir or telbivudine in preventing HBV vertical transmission for pregnancy. Medicine (Baltimore) 2019;98:e15092. [CrossRef]
• Salvadori N, Fan B, Teeyasoontranon W, et al. Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus. Clin Infect Dis 2019;69:144–146. [CrossRef]
• Bzowej NH. Optimal management of the hepatitis B patient who desires pregnancy or is pregnant. Curr Hepat Rep 2012;11:82–89. [CrossRef]
• Greenup A, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol 2014;61:502–507. https:// [CrossRef]
• Jourdain G, Ngo-Giang-Huong N, Harrison L, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med 2018;378:911–923. [CrossRef]
• Zhang L, Gui X, Wang B, et al. A study of immunoprophylaxis failure and risk factors of hepatitis B virus mother-to-infant transmission. Eur J Pediatr 2014;173:1161–1168. [CrossRef]